Page 147 - 80 guidelines for the treatment of malaria_opt

ANNEX 6. Resistance to antimalarials medicines

16. White NJ. Assessment of the pharmacodynamic properties of antimalarial drugs in vivo.
Antimicrobial Agents and Chemotherapy, 1997, 41:1413–1422.
17. Price RN et al. Risk factors for gametocyte carriage in uncomplicated falciparum malaria.
American Journal of Tropical Medicine and Hygiene, 1999, 60:1019–1023.
18. Curtis CF, Otoo LN. A simple model of the build-up of resistance to mixtures of antimalarial
drugs. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1986, 80:889–
892.
19. Hastings IM. The origins of antimalarial drug resistance. Trends in Parasitology, 2004,
20:512–518.
20. Peters W. Drug resistance – a perspective. Transactions of the Royal Society of Tropical
Medicine and Hygiene, 1969, 63:25–45.
21. Peters W. The prevention of antimalarial drug resistance. Pharmacology and Therapeutics,
1990, 47:499–508.
22. Chawira AN et al. The effect of combinations of qinghaosu (artemisinin) with standard
antimalarial drugs in the suppressive treatment of malaria in mice. Transactions of the
Royal Society of Tropical Medicine and Hygiene, 1987, 81:554–558.
23. White NJ et al. Averting a malaria disaster. Lancet, 1999, 353:1965–1967.
24. Su X et al. Complex polymorphisms in an approximately 330 kDa protein are linked to
chloroquine-resistant P. falciparum in Southeast Asia and Africa. Cell, 1997, 91:593–603.
25. Nosten F et al. Effects of artesunate-mefloquine combination on incidence of Plasmodium
falciparum malaria and mefloquine resistance in western Thailand; a prospective study.
Lancet, 2000, 356:297–302.
26. Brockman A et al. Plasmodium falciparum antimalarial drug susceptibility on the north- A6
western border of Thailand during five years of extensive artesunate-mefloquine use.
Transactions of the Royal Society of Tropical Medicine and Hygiene, 2000, 94:537–544.

133